IL-17F: The "First Responder" at the Forefront of Immune Defense

In the complex human immune system, there exists a class of cytokines dedicated to guarding the most frequently exposed "frontline fortifications"—the skin, respiratory tract, and intestinal mucosa. Among them, the IL-17F protein, as a core member of the IL-17 cytokine family, plays a pivotal "vanguard" role. It is one of the earliest signaling molecules recruited to sites of infection or injury, rapidly initiating defense programs. However, when this originally protective response becomes dysregulated, IL-17F transforms from a "guardian" into a "destroyer," becoming the central engine driving various chronic inflammatory diseases such as psoriasis, asthma, and ankylosing spondylitis. Understanding IL-17F is not only key to deciphering autoimmune diseases but also the gateway to unlocking a new generation of targeted therapies.

What is the IL-17F Protein?

Core Definition and Discovery
Interleukin-17F is a pro-inflammatory cytokine primarily produced by Th17 cells (a subset of helper T cells), γδ T cells, type 3 innate lymphoid cells (ILC3s), and certain epithelial cells. It shares the highest amino acid sequence homology (approximately 50%) with the more well-known IL-17A within its family, resulting in overlapping yet distinct functions.

Molecular Structure and Mechanism of Action
IL-17F is secreted either as a homodimer (two IL-17F molecules bound together) or as a heterodimer with IL-17A (one IL-17A and one IL-17F bound together). These different configurations may determine differences in signal strength (typically, the IL-17A homodimer has the strongest signal, the heterodimer is intermediate, and the IL-17F homodimer is relatively weaker).

Its mechanism of action is clear and direct:

Ligand Binding: IL-17F binds to the IL-17 receptor complex on the surface of target cells, which consists of the IL-17RA and IL-17RC subunits.
Signal Transduction: Upon receptor activation, it primarily triggers the ACT1-dependent pathway, subsequently activating classical inflammatory signaling pathways such as NF-κB and MAPK.
Gene Expression: Ultimately, it induces the expression of numerous downstream inflammatory factors, antimicrobial peptides, and chemokines.

Core Biological Functions: The "Conductor" of Barrier Immunity

The primary site of IL-17F action is mucosal and tissue barriers. Its key functions include:

Recruiting Neutrophils: Induces epithelial cells to produce chemokines such as CXCL1 and CXCL8, rapidly recruiting neutrophils to inflammatory sites to clear pathogens.
Enhancing Barrier Defense: Stimulates epithelial cells to produce antimicrobial peptides like β-defensins and S100 proteins, strengthening physical and chemical barriers.
Inducing Inflammatory Mediators: Promotes the production of cytokines such as GM-CSF, G-CSF, and IL-6, amplifying and sustaining inflammatory responses.
Influencing Tissue Remodeling: In certain chronic environments, it can promote the production of matrix metalloproteinases (MMPs), participating in tissue repair and pathological fibrosis.

Deep Associations Between IL-17F and Diseases

Persistent and abnormal expression of IL-17F disrupts local immune balance and is a shared pathological feature of many chronic inflammatory diseases.

1. Psoriasis and Psoriatic Arthritis
This is the most well-studied and classic example of IL-17F's role.

Core Driving Role: IL-17F levels are significantly elevated in the skin lesions and synovial fluid of psoriasis patients. Working in synergy with IL-17A, it serves as the central engine initiating and maintaining the vicious cycle of the disease.

Pathogenic Chain:
IL-17F directly acts on keratinocytes (the outermost skin cells).
Induces their abnormal proliferation (leading to epidermal thickening and scaling) and the production of large quantities of chemokines (e.g., CXCL1) and antimicrobial peptides (e.g., LL37).
Recruits more immune cells (neutrophils, Th17 cells) to infiltrate, forming a positive feedback loop that results in characteristic erythema, scales, and plaques.

Therapeutic Target Validation: Targeting the IL-17 pathway is revolutionary in psoriasis treatment. Secukinumab and ixekizumab primarily target IL-17A but also indirectly affect IL-17F. Bimekizumab, which neutralizes both IL-17A and IL-17F, has demonstrated exceptional clinical efficacy, proving the non-negligible role of IL-17F in the disease.

2. Ankylosing Spondylitis and Axial Spondyloarthritis
Mechanistic Link: IL-17F is highly expressed in the synovium and sacroiliac joint tissues of patients. It drives local inflammation, stimulates periosteal cells and osteoblasts, and participates in the seemingly contradictory yet coexisting pathological processes of new bone formation (osteophytes) and bone destruction, ultimately leading to spinal fusion and joint ankylosis.
Therapeutic Significance: IL-17 inhibitors (e.g., secukinumab) effectively alleviate AS symptoms and inhibit radiographic progression, with IL-17F contributing partially to these effects.

3. Allergic Airway Diseases
Asthma (particularly neutrophilic asthma): IL-17F is highly expressed in the airways of some severe asthma patients. It induces airway smooth muscle cell contraction, mucus hypersecretion (goblet cell hyperplasia), and recruits neutrophils, leading to airway hyperresponsiveness and steroid resistance. Therapies targeting IL-17F may offer new options for this refractory asthma subtype.
Chronic Rhinosinusitis with Nasal Polyps: IL-17F and IL-17A jointly drive a strong type 2/type 3 mixed inflammatory response in nasal polyp tissue, promoting tissue edema and polyp growth.

4. Inflammatory Bowel Disease
Crohn's Disease: In some patients, especially those with oral aphthous ulcers, IL-17F levels are elevated. It may exacerbate intestinal damage by disrupting the intestinal epithelial barrier and recruiting inflammatory cells. However, the role of the IL-17 pathway in IBD is complex, as it may have protective effects in certain stages.

5. Autoimmune Skin Diseases
Atopic Dermatitis: Although traditionally considered Th2-dominated, studies have found elevated IL-17F expression in some patients (particularly in chronic hand eczema among Asian populations), contributing to skin barrier disruption and inflammation maintenance.

6. Dual Roles in Infections and Cancer
Host Defense: In resistance to Candida albicans, Staphylococcus aureus, and extracellular bacterial infections, IL-17F is a critical protective factor in mucosal immunity. Mice lacking IL-17F are more susceptible to mucosal infections.
Tumor Microenvironment: Its role is complex. On one hand, it may promote tumor growth by enhancing inflammation and angiogenesis; on the other hand, it may augment anti-tumor immunity in certain contexts. Its value in cancer immunotherapy is under exploration.

Targeting IL-17F: New Frontiers in Precision Intervention

Dual Neutralizing Antibodies:
Bimekizumab: Currently the only approved monoclonal antibody that simultaneously targets IL-17A and IL-17F. It has shown highly effective and durable results in diseases like psoriasis, directly proving that blocking both is more advantageous than targeting IL-17A alone, leading to more thorough pathway inhibition.

Specific IL-17F Inhibitors:
These are still in development. Such drugs aim to more precisely inhibit IL-17F and may be suitable for disease subtypes primarily driven by IL-17F or where partial IL-17A function (to maintain anti-infection immunity) needs to be preserved, theoretically offering better safety profiles.

Small Molecule Inhibitors:
Oral small-molecule drugs targeting downstream signaling molecules of the IL-17 receptor (e.g., ACT1) are also being explored, potentially providing a systemic blocking approach.

IL-17F as a Biomarker: Potential Applications

Measuring IL-17F levels in tissues or blood can help:

Disease Subtyping: Identify "Th17-high" phenotype patients who are more likely to respond to IL-17-targeted therapies.
Treatment Prediction and Monitoring: High pre-treatment IL-17F levels may predict favorable responses to IL-17 inhibitors; post-treatment level declines can assess efficacy.
Prognostic Assessment: Correlates with disease activity and severity.

Future Prospects and Challenges

Advancing Precision Medicine: There is a need to more precisely define which diseases and patient subgroups are primarily driven by IL-17F to enable tailored treatment strategies.
Balancing Safety: Complete blockade of the IL-17 pathway increases risks such as Candida infections. Developing more selective inhibitors or exploring combined antifungal prophylaxis strategies are future directions.
Exploring Combination Therapies: Investigating the combined use of IL-17F inhibitors with other targeted drugs (e.g., TNF-α inhibitors, JAK inhibitors, or IL-23 inhibitors) to tackle more refractory diseases.
Novel Drug Delivery: Developing topical or inhaled IL-17F inhibitors for skin diseases or asthma to reduce systemic exposure and side effects.

Conclusion

The IL-17F protein, as an indispensable "vanguard" member of the IL-17 family, is a central hub connecting adaptive and innate immunity and safeguarding barrier health. Its discovery and study have not only revealed the shared inflammatory nature of diseases like psoriasis and ankylosing spondylitis but also catalyzed the development of groundbreaking therapies such as bimekizumab, which simultaneously neutralizes IL-17A and IL-17F. From basic research to clinical translation, the in-depth exploration of IL-17F marks the transition of autoimmune disease treatment from "broad-spectrum anti-inflammation" to a new era of "precision targeting." In the future, as its biological properties are further elucidated, IL-17F-targeted strategies will undoubtedly offer safer and more effective treatment options for patients with inflammatory diseases.